GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (NAS:ALT) » Definitions » Accounts Receivable

ALT (Altimmune) Accounts Receivable : $0.43 Mil (As of Sep. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Altimmune Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Altimmune's accounts receivables for the quarter that ended in Sep. 2024 was $0.43 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Altimmune's Days Sales Outstanding for the quarter that ended in Sep. 2024 was 7,811.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Altimmune's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was $1.76.


Altimmune Accounts Receivable Historical Data

The historical data trend for Altimmune's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altimmune Accounts Receivable Chart

Altimmune Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.02 4.61 0.43 0.17 1.11

Altimmune Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 1.11 0.31 0.42 0.43

Altimmune Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Altimmune Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Altimmune's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.428/0.005*91
=7,811.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Altimmune's accounts receivable are only considered to be worth 75% of book value:

Altimmune's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(139.38+0.75 * 0.428+0.5 * 0-14.487
-0-0)/71.1244
=1.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Altimmune Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Altimmune's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Altimmune Business Description

Traded in Other Exchanges
Address
910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Executives
David Drutz director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Richard I Eisenstadt officer: Chief Financial Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Catherine A. Sohn director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Matthew Scott Harris officer: Chief Medical Officer C/O ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Raymond M Jordt officer: Chief Business Officer ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Wayne Pisano director C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Vipin K Garg director, officer: President and CEO 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
John Gill director C/O PHARMATHENE, INC, ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
M Scot Roberts officer: Chief Scientific Officer 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Diane Jorkasky director 60 MANOR AVENUE, WELLESLEY MA 02482
Philip Hodges director 19 FIRSTFIELD RD., SUITE 200, GAITHERSBURG MD 20878
Vhcp Management Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Ii, L.p. 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Vhcp Co-investment Holdings Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018